Rare variant contribution to human disease in 281,104 UK Biobank exomes

Quanli Wang(AstraZeneca (United States)), Ryan S. Dhindsa(AstraZeneca (United States)), Keren Carss(AstraZeneca (United Kingdom)), Andrew R. Harper(AstraZeneca (United Kingdom)), Abhishek Nag(AstraZeneca (United Kingdom)), Ioanna Tachmazidou(AstraZeneca (United Kingdom)), Dimitrios Vitsios(AstraZeneca (United Kingdom)), Sri V. V. Deevi(AstraZeneca (United Kingdom)), Alex Mackay(AstraZeneca (Sweden)), Daniel Muthas(AstraZeneca (Sweden)), Michael Hühn(AstraZeneca (Sweden)), Susan J. Monkley(AstraZeneca (Sweden)), Henric Olsson(AstraZeneca (Sweden)), AstraZeneca Genomics Initiative(AstraZeneca (Sweden)), Bastian R. Angermann(AstraZeneca (United Kingdom)), Ronen Artzi(AstraZeneca (United States)), Carl Barrett(AstraZeneca (United Kingdom)), Maria G. Belvisi(AstraZeneca (Sweden)), Mohammad Bohlooly‐Y(AstraZeneca (United Kingdom)), Oliver S. Burren(AstraZeneca (Sweden)), Lisa Buvall(AstraZeneca (Sweden)), Benjamin Challis(AstraZeneca (United Kingdom)), Sophia Cameron‐Christie(AstraZeneca (United Kingdom)), E. Suzanne Cohen(AstraZeneca (Sweden)), Andrew Davis(AstraZeneca (Sweden)), Regina Fritsche Danielson(AstraZeneca (United States)), Brian Dougherty(AstraZeneca (Sweden)), Benjamin Georgi(AstraZeneca (United Kingdom)), Zara Ghazoui(AstraZeneca (Sweden)), Pernille Hansen(AstraZeneca (United Kingdom)), Fengyuan Hu(AstraZeneca (United Kingdom)), Magda Jeznach(AstraZeneca (United Kingdom)), Xiao Jiang(AstraZeneca (Sweden)), Chanchal Kumar(AstraZeneca (United States)), Zhongwu Lai(AstraZeneca (United Kingdom)), Glenda Lassi(AstraZeneca (United Kingdom)), Samuel H. Lewis(AstraZeneca (United States)), Bolan Linghu(AstraZeneca (United Kingdom)), Kieren Lythgow(AstraZeneca (United Kingdom)), Peter Maccallum(AstraZeneca (United Kingdom)), Carla Martins(AstraZeneca (United Kingdom)), Athena Matakidou(AstraZeneca (Sweden)), Erik Michaëlsson(AstraZeneca (Sweden)), Sven Moosmang(AstraZeneca (United Kingdom)), Sean M. O’Dell(AstraZeneca (United States)), Yoichiro Ohne(AstraZeneca (United Kingdom)), Joel Okae(AstraZeneca (United Kingdom)), Amanda O’Neill(AstraZeneca (United Kingdom)), Dirk S. Paul(AstraZeneca (Sweden)), Anna Reznichenko(AstraZeneca (Sweden)), Michael Snowden(AstraZeneca (Sweden)), Anna Walentinsson(AstraZeneca (United States)), Jorge Zeron(AstraZeneca (United Kingdom)), Menelas N. Pangalos(AstraZeneca (United Kingdom)), Sebastian Wasilewski(AstraZeneca (United Kingdom)), Katherine R. Smith(AstraZeneca (United Kingdom)), Ruth March(AstraZeneca (United Kingdom)), Adam Platt(AstraZeneca (United Kingdom)), Carolina Haefliger(AstraZeneca (United Kingdom)), Slavé Petrovski(AstraZeneca (Australia))
Nature
August 10, 2021
Cited by 591Open Access
Full Text

Abstract

Abstract Genome-wide association studies have uncovered thousands of common variants associated with human disease, but the contribution of rare variants to common disease remains relatively unexplored. The UK Biobank contains detailed phenotypic data linked to medical records for approximately 500,000 participants, offering an unprecedented opportunity to evaluate the effect of rare variation on a broad collection of traits 1,2 . Here we study the relationships between rare protein-coding variants and 17,361 binary and 1,419 quantitative phenotypes using exome sequencing data from 269,171 UK Biobank participants of European ancestry. Gene-based collapsing analyses revealed 1,703 statistically significant gene–phenotype associations for binary traits, with a median odds ratio of 12.4. Furthermore, 83% of these associations were undetectable via single-variant association tests, emphasizing the power of gene-based collapsing analysis in the setting of high allelic heterogeneity. Gene–phenotype associations were also significantly enriched for loss-of-function-mediated traits and approved drug targets. Finally, we performed ancestry-specific and pan-ancestry collapsing analyses using exome sequencing data from 11,933 UK Biobank participants of African, East Asian or South Asian ancestry. Our results highlight a significant contribution of rare variants to common disease. Summary statistics are publicly available through an interactive portal ( http://azphewas.com/ ).


Related Papers

No related papers found

Powered by citation graph analysis